Angeion v. Cardiac Pacemakers, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Magistrate judge recommends in a Report and Recommendation that a Minneapolis district court judge grant Angeion's motions for summary judgment and deny the Guidant subsidiary's counter motions for summary judgment of non-infringement that its Mini I and II automatic implantable cardioverter defibrillators infringe certain claims of three Angeion patents related to smaller size, smaller capacitance and "Hot Can-like" features of Angeion devices. The judge also recommends that a claim related to a fourth Angeion patent be dismissed. Angeion and CPI have up to twenty days to file responses to the report, after which time the district court judge will make a final ruling. A jury will consider sometime this fall claims of validity and enforceability of the patents, as well as any possible damages or willful infringement...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.